Navigation Links
New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
Date:1/23/2008

RARITAN, N.J., Jan. 23 /PRNewswire-USNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol hydrochloride immediate release (IR) tablets, an investigational oral analgesic for the relief of moderate to severe acute pain.

According to the American Pain Foundation, more than 25 million Americans experience acute pain each year as a result of injuries or surgeries, and a recent study estimated that 42 percent of U.S. hospital emergency department visits were due to pain-related problems.

Tapentadol is a novel investigational, centrally acting oral analgesic. It has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release and extended-release formulations.

Mu-opioid agonists are drugs that bind to mu-opioid receptors in the central nervous system. These drugs modify sensory and affective (mood) aspects of pain, inhibit the transmission of pain at the spinal cord and affect activity at parts of the brain that control how pain is perceived. Norepinephrine reuptake inhibitors are a type of central nervous system medication that increase the level of norepinephrine in the brain by inhibiting its re-absorption into nerve cells; these compounds have analgesic properties.

The submission is based on a full clinical development program for tapentadol. The program includes two Phase 3 multi-center studies that explored the efficacy and safety of multiple doses of the tapentadol IR formulation either for the treatment of acute pain in patients undergoing bunionectomy surgery or for patients with degenerative, end-stage joint disease of the hip or knee. The data from these clinical trials suggest that tapentadol has efficacy comparable to strong opioids.

Buni
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. DRAXIS Announces Application for Normal Course Issuer Bid
2. UIC College of Nursing in Peoria Now Accepting Applications for New Doctorate of Nursing Practice
3. Takeda submits new drug application for alogliptin (syr-322) in the US
4. CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
7. Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say
8. Submission of Marketing Authorisation Application for Dapoxetine in Europe
9. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
10. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Call to Occur on Wednesday, April 30 at 2 ... Vermillion, Inc.,(Nasdaq: VRML ), a molecular diagnostics company, ... improved detection of peripheral,artery disease (PAD) and to provide ... in late-stage development. The,teleconference will take place on Wednesday, ...
... ten years,after its arrival in the United States, ... surgery is coming under fire from some patients ... Last Friday, the FDA heard testimony from patients ... ranged from mild,visual distortion, to pain, to severe ...
... SPRINGFIELD, Ill., April 28 Does your child,suffer ... an opportunity to,attend a summer camp designed specifically for ... and,physicians? The American Lung Association of Illinois is planning ... sites this year.,During the week of July 6-11, our ...
... TORONTO, April 28 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" ... announced that,Dr. Tony Cruz, Chairman and Chief Executive ... Healthcare Unplugged Conference. Dr. Cruz,s,presentation will take place ... (Eastern,Time) at the Ritz-Carlton in Key Biscayne, Florida., ...
... study finds , , MONDAY, April 28 (HealthDay News) -- ... food they could ingest not only lost weight, they also ... new report. , Thirty-eight morbidly obese patients with low ... pain decreased by an average of about 44 percent six ...
... UPTON, NY - Brain-imaging studies performed in animals at ... provide researchers with clues about why an increasingly popular ... humans is abused. Using trace amounts of Salvia divinorum ... that can be smoked in the form of dried ...
Cached Medicine News:Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 3Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 4Health News:FDA Examines LASIK Surgery Complications 2Health News:Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference 2Health News:Gastric Bypass May Also Relieve Low Back Pain 2Health News:Brookhaven scientists explore brain's reaction to potent hallucinogen 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and ... "TEN", Noble Financial Capital Markets, Tenth Annual Equity ... a corporate presentation to prospective corporate partners and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ... insulin delivery systems especially for type 1 ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ... important aspects in today,s growth in the ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Novavax, Inc. (Nasdaq: NVAX ) announced today the ... (VLPS)".  The patent covers the use of influenza gene sequences for ... and future seasonal and pandemic strains of influenza viruses. , ... Novavax,s newly patented influenza ...
... Amicus Therapeutics (Nasdaq: FOLD ) will release its second quarter 2010 financial ... . The results announcement will be followed by a live conference call and ... , , ... at 5 p.m. EDT by dialing 877-303-5859 (U.S./ Canada ) or ...
Cached Medicine Technology:NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines 2NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines 3Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: